Bruker (BRKR) Lowered to Hold at BidaskClub

Bruker (NASDAQ:BRKR) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

A number of other research analysts have also issued reports on BRKR. Zacks Investment Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Evercore ISI started coverage on Bruker in a report on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 target price on the stock. BTIG Research started coverage on Bruker in a report on Friday, January 5th. They set a “buy” rating and a $42.00 target price on the stock. Leerink Swann lifted their target price on Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a report on Friday, February 9th. Finally, Morgan Stanley lowered their target price on Bruker from $35.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $32.54.

NASDAQ:BRKR opened at $30.07 on Friday. The stock has a market cap of $4,666.73, a P/E ratio of 24.85, a PEG ratio of 1.98 and a beta of 1.12. Bruker has a 52-week low of $23.57 and a 52-week high of $36.53. The company has a current ratio of 2.59, a quick ratio of 1.66 and a debt-to-equity ratio of 0.57.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.02. The firm had revenue of $530.50 million for the quarter, compared to analyst estimates of $506.74 million. Bruker had a return on equity of 26.68% and a net margin of 4.45%. Bruker’s revenue was up 12.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.46 earnings per share. sell-side analysts anticipate that Bruker will post 1.37 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can increased its stake in Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock worth $128,000 after purchasing an additional 2,878 shares in the last quarter. SG Americas Securities LLC purchased a new position in Bruker in the 4th quarter worth about $145,000. The Manufacturers Life Insurance Company increased its stake in Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after purchasing an additional 331 shares in the last quarter. Wolverine Trading LLC purchased a new position in Bruker in the 4th quarter worth about $201,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Bruker by 43.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,586 shares of the medical research company’s stock worth $226,000 after purchasing an additional 1,987 shares in the last quarter. 65.19% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply